Opinion|Videos|January 13, 2025
Main Conference Takeaways Regarding cGVHD Management
Author(s)Sergio A. Giralt, MD
Sergio A. Giralt, MD, discusses the key results from recent chronic graft-vs-host disease (cGVHD) research presented at ASH 2024 and how these findings will influence his clinical practice. He also shares his main takeaways on evolving strategies for cGVHD management.
Advertisement
Video content above is prompted by the following:
- What were the key results seen in this abstract and will they carry over to your clinical practice?
- What were your main takeaways with regard to chronic graft-vs-host disease management from ASH 2024?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss
2
Measles Cases Climb to 2000 in the US, Increasing Cases Year Over Year
3
Emerging Data Suggest Survodutide Targets Liver Fat More Rapidly Than Weight Loss: Lee Kaplan, MD, PhD
4
Survodutide Normalizes Liver Fat in 61% of Patients With MASLD in Phase 3 Trial: Lee Kaplan, MD, PhD
5